

Ref. No.: WOCK/SEC/SE/2025-26/053

16<sup>th</sup> December, 2025

<b>BSE Limited</b> Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <b>Scrip Code: 532300</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <b>NSE Symbol: WOCKPHARMA</b>
---	--

Dear Sir/Madam,

**Subject: Intimation for incorporation of a step-down subsidiaries of the Company.**

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that Wockhardt Bio AG, a subsidiary of the Company, has incorporated three new Wholly Owned Subsidiaries Wockhardt Swiss AG (Switzerland), Wockhardt Suisse USA Holding Corporation (USA) and Wockhardt Suisse USA LLC (USA). Consequent to the incorporation, Wockhardt Swiss AG, Wockhardt Suisse USA Holding Corporation and Wockhardt Suisse USA LLC have become Step-Down Subsidiaries of the Company.

The details required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1 /P/CIR/2023/123 dated July 13, 2023, are enclosed herewith as **Annexure A**.

This intimation will also be available on the Company's Website at [www.wockhardt.com](http://www.wockhardt.com)

This is for your information and records.

Thanking you,  
For **Wockhardt Limited**

**Rashmi Mamtura**  
**Company Secretary**

**Encls: A/a**

**Annexure – A:** Details required under SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

<b>Sr. No.</b>	<b>Particulars</b>	<b>Wockhardt Suisse AG</b>	<b>Wockhardt Suisse USA Holding Corporation</b>	<b>Wockhardt Suisse USA LLC</b>
i.	Name of the target entity, details in brief such as size, turnover etc	Name: Wockhardt Suisse AG Capital: CHF 100,000.00 divided into 100,000 shares of CHF 1.00 each Turnover: Not available as the entity is yet to commence business operations.	Name: Wockhardt Suisse USA Holding Corporation Capital: USD 50,000.00 divided into 1,000 shares of USD 50.00 each Turnover: Not available as the entity is yet to commence business operations.	Name: Wockhardt Suisse USA LLC Capital: USD 50,000.00 divided into 1,000 shares of USD 50.00 each Turnover: Not available as the entity is yet to commence business operations.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	Not applicable. This intimation is towards incorporation of a step-down subsidiary of Wockhardt Limited.	Not applicable. This intimation is towards incorporation of a step-down subsidiary of Wockhardt Limited.	Not applicable. This intimation is towards incorporation of a step-down subsidiary of Wockhardt Limited.
3.	Industry to which the entity being acquired Belongs.	Pharmaceuticals	Pharmaceuticals	Pharmaceuticals
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Objects of Wockhardt Suisse AG are in line with the main objects of the Company and the new entity will help to channelize the Company's antibiotic products.	Objects of Wockhardt Suisse USA Holding Corporation are in line with the main objects of the Company and the new entity will help to channelize the Company's antibiotic and other products across the United States of America.	Objects of Wockhardt Suisse USA LLC are in line with the main objects of the Company and the new entity will help to channelize the Company's antibiotic and other products across the United States of America.
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable	Not Applicable	Not Applicable

6.	Indicative time period for completion of the acquisition	Not Applicable	Not Applicable	Not Applicable
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Consideration in cash (through banking channel)	Consideration in cash (through banking channel)	Consideration in cash (through banking channel)
8.	Cost of acquisition and/or the price at which the shares are acquired	CHF 50,000.00 (50,000 shares were subscribed at CHF 1.00 per share).	USD 50,000.00 (1,000 shares were subscribed at USD 50.00 per share).	USD 50,000.00 (1,000 shares were subscribed at USD 50.00 per share).
9.	Percentage of shareholding / control acquired and /or number of shares acquired;	100% of the shares of Wockhardt Suisse AG are held by Wockhardt Bio AG, which in turn is a subsidiary of Wockhardt Limited	100% of the shares of Wockhardt Suisse USA Holding Corporation are held by Wockhardt Suisse AG which is a subsidiary of Wockhardt Bio AG, which in turn is a subsidiary of Wockhardt Limited	100% of the shares of Wockhardt Suisse USA LLC are held by Wockhardt Suisse USA Holding Corporation which is a subsidiary of Wockhardt Suisse AG, a subsidiary of Wockhardt Bio AG, which in turn is a subsidiary of Wockhardt Limited.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information.	Wockhardt Suisse AG is incorporated on 1 <sup>st</sup> December, 2025 in Zug, Switzerland as a step down subsidiary of the Company.  Wockhardt Suisse AG has not yet started its operations.	Wockhardt Suisse USA Holding Corporation is incorporated on 11th December, 2025 in Delaware, USA as a step down subsidiary of the Company.  Wockhardt Suisse USA Holding Corporation has not yet started its operations.	Wockhardt Suisse USA LLC is incorporated on 11th December, 2025 in Delaware, USA as a step down subsidiary of the Company.  Wockhardt Suisse USA LLC has not yet started its operations.
11.	Reason of delay	The delay in submission was due to an inadvertent administrative oversight and the disclosure is being made upon realisation of the omission.	The delay in submission was due to an inadvertent administrative oversight and the disclosure is being made upon realisation of the omission.	The delay in submission was due to an inadvertent administrative oversight and the disclosure is being made upon realisation of the omission.